Skip to main content
Journal cover image

Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.

Publication ,  Journal Article
Hardy, TA; Henry, RR; Forrester, TD; Kryzhanovskaya, LA; Campbell, GM; Marks, DM; Mudaliar, S
Published in: Diabetes, obesity & metabolism
August 2011

To assess changes in insulin sensitivity in non-diabetic adults with schizophrenia or schizoaffective disorder treated with olanzapine or risperidone.One hundred and thirty patients were randomly assigned to 12 weeks double-blind treatment with olanzapine or risperidone. Insulin sensitivity was measured using a two-step euglycaemic, hyperinsulinaemic clamp procedure. Whole-body adiposity was measured using dual-energy X-ray absorptiometry. The primary endpoint was the within-group change from baseline in insulin sensitivity normalized to fat-free mass (M(ffm) /I) during the clamp procedure's low-insulin phase, using an analysis of covariance model including the covariate weight change.Forty-one olanzapine-treated and 33 risperidone-treated patients completed baseline and endpoint clamp measurements. Mean M(ffm) /I during the low-insulin phase declined 9.0% (p = 0.226) in olanzapine-treated patients and 13.2% (p = 0.047) in risperidone-treated patients (between-group difference p = 0.354). During the high-insulin phase, M(ffm) /I declined 10.4% (p = 0.036) in olanzapine-treated patients and 2.1% (p = 0.698) in risperidone-treated patients (between-group difference p = 0.664). Changes in M(ffm) /I correlated inversely with changes in body weight and adiposity, which were generally higher in olanzapine-treated patients. Significant within-group increases in fasting glucose, but not haemoglobin A1c (HbA1c), were observed during olanzapine treatment. The fasting glucose change was not correlated with M(ffm) /I changes.Small, but statistically significant, decrements in insulin sensitivity were observed in olanzapine- and risperidone-treated patients at 1 of 2 insulin doses tested. Significant increases in fasting glucose and insulin and total fat mass were observed only in olanzapine-treated patients. Changes in insulin sensitivity correlated significantly with changes in weight or adiposity, but not with changes in glucose.

Published In

Diabetes, obesity & metabolism

DOI

EISSN

1463-1326

ISSN

1462-8902

Publication Date

August 2011

Volume

13

Issue

8

Start / End Page

726 / 735

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Schizophrenia
  • Risperidone
  • Olanzapine
  • Middle Aged
  • Male
  • Insulin Resistance
  • Humans
  • Glycated Hemoglobin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hardy, T. A., Henry, R. R., Forrester, T. D., Kryzhanovskaya, L. A., Campbell, G. M., Marks, D. M., & Mudaliar, S. (2011). Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes, Obesity & Metabolism, 13(8), 726–735. https://doi.org/10.1111/j.1463-1326.2011.01398.x
Hardy, T. A., R. R. Henry, T. D. Forrester, L. A. Kryzhanovskaya, G. M. Campbell, D. M. Marks, and S. Mudaliar. “Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Diabetes, Obesity & Metabolism 13, no. 8 (August 2011): 726–35. https://doi.org/10.1111/j.1463-1326.2011.01398.x.
Hardy TA, Henry RR, Forrester TD, Kryzhanovskaya LA, Campbell GM, Marks DM, et al. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes, obesity & metabolism. 2011 Aug;13(8):726–35.
Hardy, T. A., et al. “Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Diabetes, Obesity & Metabolism, vol. 13, no. 8, Aug. 2011, pp. 726–35. Epmc, doi:10.1111/j.1463-1326.2011.01398.x.
Hardy TA, Henry RR, Forrester TD, Kryzhanovskaya LA, Campbell GM, Marks DM, Mudaliar S. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes, obesity & metabolism. 2011 Aug;13(8):726–735.
Journal cover image

Published In

Diabetes, obesity & metabolism

DOI

EISSN

1463-1326

ISSN

1462-8902

Publication Date

August 2011

Volume

13

Issue

8

Start / End Page

726 / 735

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Schizophrenia
  • Risperidone
  • Olanzapine
  • Middle Aged
  • Male
  • Insulin Resistance
  • Humans
  • Glycated Hemoglobin